A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
Completed · Phase 2 · NCT05849922
Conditions: Hidradenitis Suppurativa
At a glance
- Research payments reported, 2025
- $177,097
- U.S. investigators named
- 6
- Sites paid
- 7
- Planned or actual enrollment
- 86
About the trial
- Sponsor
- Sanofi
- Tested
- SAR442970 (drug), Placebo (drug)
- Dates
- Started 2023-06-06; completion 2025-01-09
- Results posted
- Yes
This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.
From ClinicalTrials.gov, last updated 2026-01-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $177,097 in research payments for this study in 2025 (25 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ashley Cauthen, M.D. Dermatology · Ocala, FL
- Seth B. Forman, MD Dermatology · Tampa, FL
- Jessica St. John Dermatology · Westborough, MA
- Alice B. Gottlieb, M.D. Dermatology · Somers, NY
- Kathleen P. Gordon, DO Internal Medicine · Johnston, RI
- Stephen K. Tyring, MD PHD Dermatology · Webster, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Forward Clinical Trials Llc Forcare Clinical Research $68,793
- Icahn School of Medicine at Mount Sinai $31,158
- Mount Sinai School of Medicine Psychiatry $31,158
- University of Massachusetts School of Medicine $15,257
- Renstar Llc Renstar Medical Research $13,983
- Center for Clinical Studies Ltd LLP $11,709
- Clinical PArtners Llc $5,040
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.